Olema Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Olema Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Olema Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$34.6M, a 60.7% decline year-over-year.
  • Olema Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$123M, a 27.7% decline year-over-year.
  • Olema Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$96.7M, a 7.76% increase from 2022.
  • Olema Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$105M, a 47.4% decline from 2021.
  • Olema Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$71.1M, a 221% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$123M -$34.6M -$13.1M -60.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$110M -$30.4M -$10.3M -51.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$99.3M -$31M -$2.68M -9.49% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$96.7M -$26.8M -$593K -2.27% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$96.1M -$21.5M +$1.22M +5.36% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$97.3M -$20.1M +$12.8M +38.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$110M -$28.3M -$5.26M -22.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$105M -$26.2M -$4.54M -21% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$100M -$22.7M -$5.01M -28.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$95.2M -$32.9M -$16.5M -100% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$78.8M -$23M -$7.69M -50.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$71.1M -$21.6M -$11.5M -114% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$59.6M -$17.7M -$9.87M -126% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$49.7M -$16.4M -$14M -569% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$35.8M -$15.3M -$13.6M -806% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$22.1M -$10.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$7.84M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$2.45M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$1.69M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.